Marinus Pharmaceuticals Inc
NASDAQ:MRNS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Marinus Pharmaceuticals Inc
Short-Term Investments
Marinus Pharmaceuticals Inc
Short-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Marinus Pharmaceuticals Inc
NASDAQ:MRNS
|
Short-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Short-Term Investments
$10.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-8%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Short-Term Investments
$464m
|
CAGR 3-Years
53%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-13%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Short-Term Investments
$12.5B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Short-Term Investments
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Short-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Marinus Pharmaceuticals Inc
Glance View
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 113 full-time employees. The company went IPO on 2014-07-31. The firm is focused on the development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. The Company’s lead product candidate is ZTALMY (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD), which is developed for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD). Ganaxolone is a methylated analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone acts at both synaptic and extrasynaptic gamma-aminobutyric acid type A (GABAA) receptors, a target known for its anti-seizure, antidepressant, and anxiolytic potential.
